Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03256045 · OUTCOME

Best Overall Response, by Subject

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-05-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
IMWG Uniform Response Grade
Interval / dispersion
Not reported
Time frame
14 months

What was measured

Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. Key: 1 = very good partial response (VGPR); 2 = partial response (PR); 3 = minimal response (MR); 4 = stable disease (SD); 5 = progressive disease (PD). Please see IC50 and CI results in the other primary outcome measures.

Groups in this outcome

Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone

Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone9

Reported measurements

Subject MM-82
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone4Not reportedNot reportedNot reportedNot reported
Subject MM-91
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone2Not reportedNot reportedNot reportedNot reported
Subject MM-92
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone2Not reportedNot reportedNot reportedNot reported
Subject MM-95
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1Not reportedNot reportedNot reportedNot reported
Subject MM-96
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1Not reportedNot reportedNot reportedNot reported
Subject MM-98
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1Not reportedNot reportedNot reportedNot reported
Subject MM-99
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone3Not reportedNot reportedNot reportedNot reported
Subject MM-109
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone4Not reportedNot reportedNot reportedNot reported
Subject M-111
Values in IMWG Uniform Response Grade · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Subject MM-82
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Subject MM-91
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Subject MM-92
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Subject MM-95
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Subject MM-96
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Subject MM-98
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Subject MM-99
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Subject MM-109
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Subject M-111
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. Key: 1 = very good partial response (VGPR); 2 = partial response (PR); 3 = minimal response (MR); 4 = stable disease (SD); 5 = progressive disease (PD). Please see IC50 and CI results in the other primary outcome measures.
groups
  1. description
    Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
param Type
NUMBER
reporting Status
POSTED
time Frame
14 months
title
Best Overall Response, by Subject
type
PRIMARY
unit Of Measure
IMWG Uniform Response Grade

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice